Prime Therapeutics hires Sid Sahni to lead enterprise strategy, corporate development

News provided by

Jan 22, 2019, 14:00 ET

EAGAN, Minn., Jan. 22, 2019 /PRNewswire/ -- Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM) serving more than 27 million members nationally, welcomed Sid Sahni as its new senior vice president (SVP), Chief Strategy and Corporate Development Officer. In this position, Sahni is responsible for overall corporate strategic planning and execution. He will also lead the assessment of corporate development initiatives such as acquisitions or partnerships.

Sid Sahni, newly announced senior vice president (SVP), Chief Strategy and Corporate Development Officer.

Sahni brings more than 20 years of experience in health care and pharmacy benefits management to Prime. Most recently, he served as vice president, enterprise strategy at Aetna. In that role he was responsible for overall strategy development, including merger and acquisition strategy. He also spent eight years at CVS Health in a variety of strategy, marketing, and product development roles. Prior to that, he was a strategy consultant in the healthcare practice at Strategy& and BCG.

"Sid is an impressive leader with a long track record of driving strong results for the companies he's worked for," said Jim DuCharme, Prime's president and chief executive officer. "Sid will lend important focus to growing our business during an exciting time in today's everchanging marketplace."

Sahni holds a bachelor's degree from Goshen College in Goshen, Ind. and a master's degree in business administration (MBA) from the University of Michigan in Ann Arbor, Mich.

About Prime Therapeutics
Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and offers clinical services for people with complex medical conditions. Prime serves more than 27 million people. It is collectively owned by 18 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. For more information, visit www.primetherapeutics.com or follow @PrimePBM on Twitter.